Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Companies Commented On
- Cempra Inc.
- Concert Pharmaceuticals
- CTI BioPharma
- Intra-Cellular Therapies Inc.
- Paratek Pharmaceuticals Inc.
Robert (Bert) Hazlett, a biopharmaceuticals senior research analyst, joined ROTH Capital Partners in 2012. Hazlett has more than 15 years of equity research experience covering the biopharmaceuticals sector. Prior to joining ROTH, Hazlett was a managing director and senior analyst at BMO Capital Markets, covering both the large capitalization and emerging pharmaceuticals sectors. Before BMO, he covered similar sectors as a managing director at SunTrust Robinson Humphrey, as a vice president at Robertson Stephens, and also held analyst positions in healthcare research at Lehman Brothers and UBS Securities. Hazlett received his master's degree in business administration (finance) in 1996 from Columbia University and a bachelor's degree in economics in 1987 from Yale University.
The Small-Cap Biotech Watchlist 2015 Unwrapped: Who Are These Guys? And Why Are They Here? (1/27/15) At the Biotech Showcase 2015 in San Francisco, five biotech analysts examined the burgeoning small-cap life sciences marketplace and found every reason to believe its good health would continue into 2015 and beyond. The experts also sent investors who attended the panel discussion of The Life Sciences Report's 2015 Small-Cap Biotech Watchlist home with a bundle of robust investment opportunities, including a few new names. Read on to see which companies made the list, and why.
Meet High Risk and High Reward, Biotech's Profit Partners: Bert Hazlett (7/25/13) Small-cap biotech investing carries real risk. Startup companies tend to have only a few ideas in development, which leaves ample room for setbacks—even room for disaster. Robert "Bert" Hazlett, senior biotechnology research analyst with ROTH Capital Partners, doesn't mind taking such risks, but tempers them with a diversification strategy designed to minimize the impact of potential hiccups and blowups. In this interview with The Life Sciences Report, Hazlett expands on his strategy and mentions four companies with experienced management teams and high hopes for huge returns.
"INO has a broad platform that includes an IL-12 DNA vaccine and other DNA vaccines for both cancer and infectious diseases." (6/24/15) Inovio Pharmaceuticals Inc. - The Life Sciences Report Interview with George Zavoico More >
"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older." (6/17/15) Sunesis Pharmaceuticals Inc. - The Life Sciences Report Interview with Joe Pantginis More >
"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better." (6/17/15) Can-Fite BioPharma Ltd. - The Life Sciences Report Interview with Joe Pantginis More >